Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Pathogenesis and Clinical Relevance of Diffuse Large B-Cell Lymphoma Proteogenotypes

Blood (2024) 144 (Supplement 1): 229.

https://doi.org/10.1182/blood-2024-204606

Published: 2024

Journal Articles

Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Andrew J Davies, Josh Caddy, Katy McLaughlin, Christopher Wignall, Robert Waugh, Graham P. Collins, Louise Stanton, Geoff N Saunders, Thomas Cummin, Anna Schuh, Kirit M. Ardeshna, Andrew K. McMillan, John Radford, David John Lewis, Adam R Coleman, Gareth Griffiths, Cathy Burton, Sharon Barrans, Peter Johnson

Blood (2022) 140 (Supplement 1): 9478–9479.

https://doi.org/10.1182/blood-2022-163499

Published: 2022

Journal Articles

Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy

Blood (2022) 140 (Supplement 1): 1770–1772.

https://doi.org/10.1182/blood-2022-159976

Published: 2022

Journal Articles

Quality of Life Trajectories in Patients Treated with R-CHOP for Diffuse Large B-Cell Lymphoma As Part of the Remodl-B Trial (ISRCTN 51837425)

Joanna Hack, Inês Ralha, Sam Wilding, Louise Stanton, Josh Caddy, Sharon Barrans, Christoph Mamot, Urban Novak, Cathy Burton, Pamela McKay, Gavin Campbell, Andrew Davies, Peter Johnson

Blood (2022) 140 (Supplement 1): 6648–6649.

https://doi.org/10.1182/blood-2022-159442

Published: 2022

Journal Articles

Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Andrew Davies, Josh Caddy, Katy Mercer, Geoff N Saunders, Louise Stanton, Graham P. Collins, MD DPhil, Thomas E C Cummin, MRCP MBBCh BSc, Anna Schuh, MD MRCP, PhD, Kirit M. Ardeshna, Andrew McMillan, John A. Radford, MD FMedSci, David John Lewis, MD, Adam Coleman, Gareth Griffiths, Cathy Burton, MBBChir, MA, MD FRCPath, Sharon Barrans, Peter Johnson, MD FRCP

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-134546

Published: 2020

Journal Articles

Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel

Blood (2019) 134 (Supplement_1): 2769.

https://doi.org/10.1182/blood-2019-124352

Published: 2019

Journal Articles

Longitudinal Analyses of the Genomic, Transcriptomic, and T Cell Repertoire in Diffuse Large B Cell Lymphoma Demonstrates Changes in Signaling and Immune Recognition at Relapse

Blood (2017) 130 (Supplement 1): 2734.

https://doi.org/10.1182/blood.V130.Suppl_1.2734.2734

Published: 2017

Journal Articles

Parsimonious Gene Correlation Network Analysis in DLBCL Allows Refined Linkage to Mutation State and Treatment Response

Matthew A Care, PhD MSc, BSc, Sharon Barrans, Michael A Bentley, Ming Wang, Alexandra Clipson, Ming-Qing Du, Cathy H Burton, Josh Caddy, Andrew J Davies, PhD, Peter Johnson, David R Westhead, Reuben M Tooze

Blood (2017) 130 (Supplement 1): 2824.

https://doi.org/10.1182/blood.V130.Suppl_1.2824.2824

Published: 2017

Journal Articles

Similarity Search Methods As an Alternative to Sub-Type Characterisation in Aggressive Lymphomas

Chulin Sha, PhD, Sharon Barrans, PhD, Andrew Jack, Cathy H Burton, Alexandra Smith, PhD, Eve Roman, Dan Painter, Simon Crouch, PhD, Reuben M Tooze, PhD FRCP, Matthew Care, PhD, David R Westhead, PhD

Blood (2016) 128 (22): 3052.

https://doi.org/10.1182/blood.V128.22.3052.3052

Published: 2016

Journal Articles

Defining Immune Response Signatures in DLBCL As Potential Predictive Biomarkers for Outcome to Immunotherapy

Matthew A Care, PhD, Stephen M Thirdborough, PhD, Andrew J Davies, MRCP PhD, Peter W.M. Johnson, FRCP, Andrew Jack, PhD MB, Sharon Barrans, PhD, David R Westhead, PhD, Mark S Cragg, PhD, Reuben M Tooze, PhD FRCP, Stephen A Beers, PhD

Blood (2015) 126 (23): 2663.

https://doi.org/10.1182/blood.V126.23.2663.2663

Published: 2015

Journal Articles

Association of Gene Expression Profiling, Interim PET, EBV Status and PD-L1 Expression in Classical Hodgkin Lymphoma

Ralph Schwiebert, MBBS, Sharon Barrans, PhD, Jan Taylor, Andrew S Jack, Cathy H Burton

Blood (2015) 126 (23): 1437.

https://doi.org/10.1182/blood.V126.23.1437.1437

Published: 2015

Journal Articles

Poor Outcomes in HIV Negative and HIV Positive Patients with Plasmablastic Lymphoma (PBL) in a Population Based Patient Study

Niamh Appleby, Ruth Cullen, Dan Painter, Alexandra Smith, Eve Roman, Sharon Barrans, PhD, Sheila J.M. O'Connor, Catherine H Burton, Andrew S Jack, Roger G Owen, Reuben M Tooze, PhD FRCP

Blood (2015) 126 (23): 3924.

https://doi.org/10.1182/blood.V126.23.3924.3924

Published: 2015

Journal Articles

B-Cell Lymphopenia and Circulating Neoplastic B-Cell Populations Are Associated with High Risk Disease in DLBCL: Results from the UK Remodl-B Trial

Ruth Mary de Tute, PhD FRCPath, Sharon Barrans, PhD, Andy C. Rawstron, PhD, Christopher T Manbridge, Josh Caddy, Keith Pugh, PhD, Peter W.M. Johnson, FRCP, Andrew J Davies, MRCP, Andrew Jack, PhD MB

Blood (2015) 126 (23): 2669.

https://doi.org/10.1182/blood.V126.23.2669.2669

Published: 2015

Journal Articles

A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

Andrew J Davies, MRCP PhD, Josh Caddy, Tom Maishman, Sharon Barrans, PhD, Christoph Mamot, MD, Matthew Care, PhD, Christopher Pocock, Louise Stanton, PhD, Debbie Hamid, Keith Pugh, PhD, Andrew McMillan, PhD, Paul Fields, MDPhD, Anton Kruger, Andrew Jack, PhD MB, Peter W. M. Johnson, FRCP

Blood (2015) 126 (23): 812.

https://doi.org/10.1182/blood.V126.23.812.812

Published: 2015

Journal Articles

Early Diagnosis of Myelodysplastic Syndromes Can be Improved By Deep Sequencing and Array Based Cytogenetics

Catherine Cargo, MB FRCPath, Nicola Rowbotham, PhD, Paul Evans, PhD, Sharon Barrans, PhD, Simon Crouch, PhD, Andrew Jack, PhD

Blood (2014) 124 (21): 167.

https://doi.org/10.1182/blood.V124.21.167.167

Published: 2014

Journal Articles

Patients With DLBCL Commonly Have B-Cell Lymphopenia and Circulating Clonal B-Cell Populations With a Phenotype Concordant With The Underlying Tumour

Ruth M de Tute, MSc, Sharon Barrans, PhD, Andy C. Rawstron, PhD, Peter W.M. Johnson, MD, FRCP, Andrew J Davies, MRCP, PhD, Andrew Jack, PhD

Blood (2013) 122 (21): 3013.

https://doi.org/10.1182/blood.V122.21.3013.3013

Published: 2013

Journal Articles

Development Of A Cross Platform, 2-Way Gene Expression Classifier To Distinguish Burkitt Lymphoma From DLBCL, and Assessment Of The Potential Impact Of Its Use In Treatment Decision Making

Sharon Barrans, PhD, Sha Chulin, Alex Smith, Simon Crouch, MA PhD, Lisa Worrillow, PhD, Eve Roman, PhD, David Westhead, PhD, Andrew Jack, PhD

Blood (2013) 122 (21): 74.

https://doi.org/10.1182/blood.V122.21.74.74

Published: 2013

Journal Articles

Meta-Analysis of Diffuse Large B-Cell Lymphoma Gene Expression Identifies Novel and Recurrent Biological Connections,

Matthew Care, PhD, Sharon Barrans, PhD, Lisa Worrillow, Andrew Jack, PhD, MB, David Westhead, PhD, Reuben Tooze, PhD

Blood (2011) 118 (21): 3682.

https://doi.org/10.1182/blood.V118.21.3682.3682

Published: 2011

Journal Articles

RQ-PCR Provides a Superior Alternative to Immunohistochemistry In Defining Prognostic Groups In DLBCL, and Predicts Treatment Failure with CHOP-R

Lisa Worrillow, Sharon Barrans, Simon Crouch, Matthew Care, Alex Smith, Russell Patmore, Reuben Tooze, Eve Roman, Andrew Jack

Blood (2010) 116 (21): 2484.

https://doi.org/10.1182/blood.V116.21.2484.2484

Published: 2010

Journal Articles

Gene Expression Profiling Using the Illumina ‘DASL’ Platform on RNA Extracted From Formalin Fixed Paraffin Embedded (FFPE) Tissue Identifies Distinct Prognostic Groups In CHOP-R Treated DLBCL

Sharon Barrans, Lisa Worrillow, Matthew Care, Simon Crouch, Alex Smith, Russell Patmore, Andrew Davies, Reuben Tooze, Eve Roman, Andrew Jack

Blood (2010) 116 (21): 2485.

https://doi.org/10.1182/blood.V116.21.2485.2485

Published: 2010

NARROW

Pathogenesis and Clinical Relevance of Diffuse Large B-Cell Lymphoma Proteogenotypes

Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy

Quality of Life Trajectories in Patients Treated with R-CHOP for Diffuse Large B-Cell Lymphoma As Part of the Remodl-B Trial (ISRCTN 51837425)

Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel

Longitudinal Analyses of the Genomic, Transcriptomic, and T Cell Repertoire in Diffuse Large B Cell Lymphoma Demonstrates Changes in Signaling and Immune Recognition at Relapse

Parsimonious Gene Correlation Network Analysis in DLBCL Allows Refined Linkage to Mutation State and Treatment Response

Similarity Search Methods As an Alternative to Sub-Type Characterisation in Aggressive Lymphomas

Defining Immune Response Signatures in DLBCL As Potential Predictive Biomarkers for Outcome to Immunotherapy

Association of Gene Expression Profiling, Interim PET, EBV Status and PD-L1 Expression in Classical Hodgkin Lymphoma

Poor Outcomes in HIV Negative and HIV Positive Patients with Plasmablastic Lymphoma (PBL) in a Population Based Patient Study

B-Cell Lymphopenia and Circulating Neoplastic B-Cell Populations Are Associated with High Risk Disease in DLBCL: Results from the UK Remodl-B Trial

A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

Early Diagnosis of Myelodysplastic Syndromes Can be Improved By Deep Sequencing and Array Based Cytogenetics

Patients With DLBCL Commonly Have B-Cell Lymphopenia and Circulating Clonal B-Cell Populations With a Phenotype Concordant With The Underlying Tumour

Development Of A Cross Platform, 2-Way Gene Expression Classifier To Distinguish Burkitt Lymphoma From DLBCL, and Assessment Of The Potential Impact Of Its Use In Treatment Decision Making

Meta-Analysis of Diffuse Large B-Cell Lymphoma Gene Expression Identifies Novel and Recurrent Biological Connections,

RQ-PCR Provides a Superior Alternative to Immunohistochemistry In Defining Prognostic Groups In DLBCL, and Predicts Treatment Failure with CHOP-R

Gene Expression Profiling Using the Illumina ‘DASL’ Platform on RNA Extracted From Formalin Fixed Paraffin Embedded (FFPE) Tissue Identifies Distinct Prognostic Groups In CHOP-R Treated DLBCL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only